Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 9 Paclitaxel 8 Capecitabine 8 trastuzumab deruxtecan 7 Fulvestrant 7 pertuzumab 5 eribulin 5 Gemcitabine 5 Cyclophosphamide 5 130-nm albumin-bound paclitaxel 5 Doxorubicin 4 Carboplatin 4 Ado-Trastuzumab Emtansine 4 sacituzumab govitecan 3 ribociclib 3 Vinorelbine 3 Epirubicin 3 Docetaxel 3 selpercatinib 2 pembrolizumab 2 palbociclib 2 olaparib 2 neratinib 2 larotrectinib 2 exemestane 2 capivasertib 2 abemaciclib 2 Letrozole 2 Fluorouracil 2 Anastrozole 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × RAD1901 × Breast × Clear all

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡